These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 24922007

  • 1. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
    Pasello G, Urso L, Silic-Benussi M, Schiavon M, Cavallari I, Marulli G, Nannini N, Rea F, Ciminale V, Favaretto A.
    J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
    [Abstract] [Full Text] [Related]

  • 2. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.
    Int J Cancer; 2013 Jan 15; 132(2):459-71. PubMed ID: 22532243
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 15; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 5. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
    Anraku M, Tagawa T, Wu L, Yun Z, Keshavjee S, Zhang L, Johnston MR, de Perrot M.
    J Immunol; 2010 Jul 15; 185(2):956-66. PubMed ID: 20548032
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.
    Br J Cancer; 2011 Nov 08; 105(10):1542-53. PubMed ID: 21970874
    [Abstract] [Full Text] [Related]

  • 8. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
    Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G.
    Oncotarget; 2017 Jul 04; 8(27):44232-44241. PubMed ID: 28562336
    [Abstract] [Full Text] [Related]

  • 9. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.
    Cancer Res; 2002 Oct 15; 62(20):5800-6. PubMed ID: 12384541
    [Abstract] [Full Text] [Related]

  • 10. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A, Calvert P, Azzabi A, Plummer R, Johnson R, Rusthoven J, Griffin M, Fishwick K, Boddy AV, Verrill M, Calvert H.
    J Clin Oncol; 2002 Aug 15; 20(16):3533-44. PubMed ID: 12177114
    [Abstract] [Full Text] [Related]

  • 11. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.
    Su L, Liu G, Hao X, Zhong N, Zhong D, Liu X, Singhal S.
    Eur J Cancer; 2011 Nov 15; 47(16):2471-8. PubMed ID: 21726997
    [Abstract] [Full Text] [Related]

  • 12. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
    Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A.
    Clin Cancer Res; 2011 Apr 15; 17(8):2581-90. PubMed ID: 21262916
    [Abstract] [Full Text] [Related]

  • 13. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J, Wang Y, Chen D, Ji G, Ma Q, Liao S, Zheng Y, Zhang J, Hou Y.
    Cancer Lett; 2016 Dec 28; 383(2):145-153. PubMed ID: 27721019
    [Abstract] [Full Text] [Related]

  • 14. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S.
    Clin Cancer Res; 2007 Oct 01; 13(19):5918-25. PubMed ID: 17908988
    [Abstract] [Full Text] [Related]

  • 15. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul 01; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 16. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 17. A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.
    Kao SC, McCaughan B, Muljono A, Boyer M.
    J Thorac Oncol; 2010 Mar 01; 5(3):405-6. PubMed ID: 20186029
    [No Abstract] [Full Text] [Related]

  • 18. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 19. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):549-58. PubMed ID: 17522864
    [Abstract] [Full Text] [Related]

  • 20. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.
    Int J Mol Med; 2012 Nov 01; 30(5):1087-94. PubMed ID: 22922573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.